Redenlab partners with BDCRC to support new NIH-funded Batten disease research
A newly formed research network focused on Batten disease, a rare and inherited brain disorder that primarily affects…
speech
Latest content
Redenlab contributes to position paper on advancing digital healthtechnologies for frontotemporal degeneration
MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap…
Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research
Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research
Redenlab’s Chief Science Officer, Adam P. Vogel, PhD, leads groundbreaking study on speech analysis for neurodegenerative diseases
MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a…
Childhood apraxia of speech clinical trial
Speech disorders impacting children have debilitating impacts on educational, social and later employment outcomes. There are limited therapeutic…
Researchers working towards finding a new treatment for Spinocerebellar Ataxia Type 1 (SCA1)
Spinocerebellar ataxia Type 1 (SCA1) is a dominantly inherited neurodegenerative disease resulting in balance, speech, thinking and coordination…
The FA App
Friedreich ataxia (FA) is a progressive, genetically inherited multisystem disease that affects children and adults. FA leads to…
TRACK-FA Study
Friedreich ataxia (FA) is an inherited, multisystem neurodegenerative disease that results in profound changes to speech, swallowing, balance,…
Professor Angela Morgan leads the Translational Centre for Speech Disorders in groundbreaking NHMRC CRE research program
Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that…
Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)
Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA…
Redenlab shines in Huberman Podcast, unveiling cannabis study and speech analysis expertise
MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The…
The L16HTHOUSE Study
L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays…
Dietary fat supplement trial for A-T
Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts…
Temporary Assessment of Language in Kabuki Syndrome (TALK) Study
Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate…
ARIAS: Zooming in on eye-based biomarkers for Alzheimer’s
Scientists are turning to retinas as a potential screening target for early signs of Alzheimer’s, an incurable neurodegenerative…
How important is stability in your speech measures?
In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and…
Exploring the speech and language of individuals with non‐syndromic submucous cleft palate: a preliminary report
BackgroundSubmucous cleft palate (SMCP) has a heterogeneous presentation and is often identified late or misdiagnosed. Diagnosis is prompted…
Redenlab sign agreement with Monash Institute of Cognitive and Clinical Neurosciences
Redenlab are working with the Monash University Sleep group
Redenlab commence work with Royal Melbourne Hospital on mobile speech recording in multiple sclerosis
In collaboration with the Movement Disorders and Cognitive monitoring in MS group. Speech is being used as an…
Redenlab sign contract with Koneksa Health & Takeda Pharmaceuticals
Redenlab are partnering with Koneksa Health to provide speech testing to Takeda Pharmaceuticals USA on a multi-site trial…
